Methods and compositions involving NKG2D inhibitors and cancer

• US 10,040,853 B2
• Filed: 09/07/2012
• Issued: 08/07/2018
• Est. Priority Date: 09/09/2011
• Status: Active Grant

• Current Assignee: Fred Hutchinson Cancer Research Center (Fred Hutchinson Cancer Research Center|Argus Genetics|Mars)
• Original Assignee: Fred Hutchinson Cancer Research Center (Fred Hutchinson Cancer Research Center|Argus Genetics|Mars)
• Inventors: Spies, Thomas, Spies, Veronika
• Primary Examiner(s): Xiao, Yan
• Application Number:
  US14/343,543
• Publication Number:
  US 20140377266A1
• Time in Patent Office: 2,160 Days
• Field of Search: 4241351
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/2815 against CD8
• CPC Class Codes: C07K 16/2833 against MHC-molecules, e.g. HLA-molecules
• CPC Class Codes: C07K 16/2851 against the lectin superfamily, e.g. CD23, CD72
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2330/51 Specially adapted vectors

Abstract

Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer.

Claims

1. A method for inhibiting tumor progression, the method comprising administering to a subject that has been determined to have NKG2D-expressing cancer cells a composition comprising an anti-NKG2D ligand antibody or NKG2D ligand-binding polypeptide.

2. The method of claim 1, wherein the NKG2D ligand antibody or ligand binding polypeptide inhibitor interferes with the NKG2D-binding of one or more endogenous NKG2D ligands on a cancer cell.

3. The method of claim 1, wherein the polypeptide is an isolated antibody.

4. The method of claim 3, wherein the isolated antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or a single chain antibody.

5. The method of claim 3, wherein the isolated antibody is a human antibody.

10. The method of claim 1, wherein the ligand comprises MIC or ULBP.

12. The method of claim 1, wherein the cancer cells comprise ovarian, breast, prostate, or colon cancer cells.

14. The method of claim 1, wherein the method comprises administering to the subject a composition comprising a NKG2D ligand-binding polypeptide.

6. A method for treating cancer comprising administering to NKG2D-expressing cancer cells in a subject that has been determined to have NKG2D-expressing cancer cells a composition comprising an anti-NKG2D ligand antibody or NKG2D ligand-binding polypeptide.

7. The method of claim 6, wherein the polypeptide is an isolated antibody.

8. The method of claim 7, wherein the isolated antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or a single chain antibody.

9. The method of claim 7, wherein the isolated antibody is a human antibody.

11. The method of claim 6, wherein the ligand comprises MIC or ULBP.

13. The method of claim 6, wherein the cancer cells comprise ovarian, breast, prostate, or colon cancer cells.